AXL and hematologic disorder: It operates by impeding tumor metastasis and angiogenesis through the inhibition of Axl and its subsequent Akt phosphorylation.[234] Moreover, Bemcentinib has the capability to enhance sensitivity to mitotic inhibitors like Docetaxel, resulting in superior antitumor effects.[235] To date, Bemcentinib has exhibited promising efficacy in a diverse array of solid tumors and hematological malignancies, either independently or in combinatorial treatments with other medications (NCT02922777/NCT03184571/NCT02488408).